From the Guidelines
Dupilumab is more effective than benralizumab for the treatment of chronic rhinosinusitis with nasal polyposis, as it improves quality of life, symptoms, smell, and decreases the need for oral corticosteroids and surgery. When comparing the two biologics, dupilumab has been shown to have a more significant impact on quality of life, with studies showing that dupilumab > omalizumab > mepolizumab > benralizumab in terms of quality of life improvement 1. In terms of symptoms, dupilumab also demonstrates superiority, with dupilumab > omalizumab > mepolizumab in symptom improvement 1. Additionally, dupilumab has been shown to improve smell, with dupilumab > mepolizumab > omalizumab > benralizumab in terms of smell improvement 1. It is essential to consider the patient's specific needs and comorbidities when choosing between these medications, as dupilumab may be more favorable for those with other conditions that are treated with biologics. Some key points to consider when deciding between benralizumab and dupilumab include:
- Quality of life improvement: dupilumab has been shown to have a more significant impact on quality of life
- Symptom improvement: dupilumab demonstrates superiority in symptom improvement
- Smell improvement: dupilumab has been shown to improve smell more significantly than benralizumab
- Decrease in need for oral corticosteroids and surgery: dupilumab has been shown to decrease the need for these interventions more significantly than benralizumab 1.
From the Research
Comparison of Benralizumab and Dupilumab
- The effectiveness of benralizumab versus dupilumab in treating severe asthma has been compared in several studies 2, 3, 4, 5.
- A real-world study found that dupilumab was associated with a 24% and 28% significant reduction in the risk of severe asthma exacerbations versus benralizumab and mepolizumab, respectively 3.
- Another study found that all biologics, including benralizumab and dupilumab, led to significant improvements in pulmonary function, asthma control test score, and oral corticosteroid dose, with no clinically relevant advantage for any antibody 4.
- A matching-adjusted indirect comparison found that benralizumab demonstrated efficacy comparable to dupilumab for oral corticosteroid dosage reduction, oral corticosteroid elimination, and annual exacerbation rate reduction 5.
Efficacy of Benralizumab and Dupilumab
- Benralizumab has been shown to lead to significant improvements in clinical outcome measures, including a 72.8% reduction in annualized exacerbation rate and a 51.4% reduction in median daily prednisolone dose 6.
- Dupilumab has also been shown to be effective in treating severe asthma, with a significant improvement in FEV1 and asthma control test score, and a high overall response rate of 77.8% 2.
- Both benralizumab and dupilumab have been found to be effective in reducing oral corticosteroid use and improving asthma control, with similar outcomes between groups after 6 and 12 months of treatment 4.
Real-World Effectiveness
- Real-world studies have found that both benralizumab and dupilumab are effective in treating severe asthma, with significant improvements in clinical outcome measures and high response rates 3, 6.
- The real-world effectiveness of benralizumab and dupilumab may be influenced by baseline characteristics, such as eosinophilic phenotype and disease severity 6.
- Further studies are needed to fully characterize the comparative effectiveness of benralizumab and dupilumab in real-world settings 3, 4, 5.